Drug Trial Radar · NCT05497804
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
17
Actual
Start
Sep 22, 2022
Primary completion
Feb 12, 2026
Study completion Sep 4, 2028
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Aug 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help determine if patients who have a small amount of cancer left after the initial treatment, called minimal residual disease, will benefit from the drug combination.
Conditions
- ISS Stage III Plasma Cell Myeloma
- Multiple Myeloma
Interventions
Bone Marrow Aspiration and BiopsyProcedure
Undergo bone marrow aspiration and biopsy
CarfilzomibDrug
Given IV
Computed TomographyProcedure
Undergo CT or PET/CT
DaratumumabBiological
Given SC
DexamethasoneDrug
Given IV/PO
LenalidomideDrug
Given PO
Magnetic Resonance ImagingProcedure
Undergo MRI
Positron Emission TomographyProcedure
Undergo PET/CT
Multigated Acquisition ScanProcedure
Undergo MUGA scan
Biospecimen CollectionProcedure
Undergo blood sample collection
EchocardiographyProcedure
Undergo ECHO
Chest RadiographyProcedure
Undergo chest x-ray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Sustained Minimal Residual Disease (MRD) NegativityTime frame: 1 year
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Scottsdale, Arizona
Mayo Clinic
Jacksonville, Florida
Mayo Clinic in Rochester
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.